Penthrox in Rezūm BPH

Inclusion Criteria: * Male subjects of ≥ 18 years of age * Patient who has elected Convective Thermal Therapy using Rezūm System for the management of their benign prostatic hyperplasia. * No contra-indication on using Methoxyflurane inhaler (Penthrox™). * Willing and able to accurately complete the required questionnaires. * Willing and able to provide signed and dated informed consent. Exclusion Criteria: * Ongoing use of analgesic agents for chronic pain. * Concomitant use of nephrotoxic agents. * INR \> 4. * Use of Methoxyflurane inhaler (Penthrox™) within the previous 3 months. * Known allergy to Lorazepam, Percocet/ Oxycodone, or Xylocaine® gel. * Known personal or familial hypersensitivity to Methoxyflurane inhaler (Penthrox™) or other halogenated anesthetics. * Clinically significant respiratory depression, cardiovascular instability, renal or hepatic impairment. * An altered level of consciousness, due to any cause, including head injury, drugs, or alcohol. * Known or genetically susceptible to malignant hyperthermia or a history of severe adverse reactions in either patient or relatives. * A history of liver dysfunction after previous Methoxyflurane inhaler (Penthrox™) use or other halogenated anesthetics.